Publication | Closed Access
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma
62
Citations
21
References
2018
Year
Cabergoline was an effective drug for treating residual NFPA, and its use was associated with a high rate of tumor shrinkage (ClinicalTrials.gov NCT03271918).
| Year | Citations | |
|---|---|---|
Page 1
Page 1